INTRODUCTION: Drug-related mortality is a key epidemiological indicator that is collected nationally and internationally. Significant efforts were made in 2006-2007 to improve the quality of data concerning drug-related mortality in the Czech Republic. The aim of this article is to identify the effect of a quality improvement project on the drug-induced mortality data reported in the General Mortality Registry (GMR), and to demonstrate how to identify, quantify and interpret changes in drug-induced mortality based on the example of the Czech Republic. METHODS: We extracted data on illicit drug-induced deaths from the Czech Republic GMR and Special Mortality registry (SMR) for the years between 2004 and 2012, and aggregated monthly and quarterly time series. We applied a new procedure to identify structural breakpoints in time series based on dating structural changes in standard linear regression models. RESULTS: In the GMR, breakpoints were identified in three time series: (i) opioid-related deaths; (ii) other stimulant-related deaths; and (iii) total drug-induced deaths. In the SMR, the structural breaks were identified for opioids, volatile substances and selection D time series. In each of these time series, the analysis identified a decrease in the intercepts in the different segments. DISCUSSION AND CONCLUSIONS: The structural breaks identified and quantified in the GMR time series were plausibly caused by the quality improvement efforts that started in 2006. These results demonstrate that it is critical for the analysis and use of drug mortality data collected in the registries to identify practice changes in the relevant registries, to quantify their influence and to adjust mortality estimates accordingly.

Department of Addictology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Public Health Sciences University of Connecticut School of Medicine Farmington USA

National Institute of Mental Health Klecany Czech Republic

National Monitoring Centre for Drugs and Addiction Office of the Government of the Czech Republic Prague Czech Republic

Zobrazit více v PubMed

European Monitoring Centre for Drugs and Drug Addiction. Drug-related deaths and mortality in Europe: update from the EMCDDA expert network. Luxembourg: EMCDDA, 2019.

Commission on Narcotic Drugs. Drug information systems: principles, structures and indicators (Lisbon Consensus) (Commission on Narcotic Drugs, Forty-Third Session, Item 4(a) and (b) of the Provisional Agenda E/CN.7/2000/CRP.3). Commission on Narcotic Drugs; 2000.

Griffiths P, Mounteney J. Drug trend monitoring. In: Miller PG, Strang J, Miller PM, eds. Addiction research methods. Oxford: Wiley-Blackwell, 2010:337-54.

European Monitoring Centre for Drugs and Drug Addiction. Drug-related deaths (DRD) standard protocol, version 3.2. EMCDDA; 2010.

Petruželka B, Barták M. Potential indicators for the analysis of the association between public health and drug market policing in The Czech Republic: review of public health indicators. Adiktologie 2019;19:135-43.

Poppová M, Štyglerová T. Statistika zemřelých podle příčin smrti se změnila. 5; 2012.

Zábranský T. Národní monitorovací středisko pro drogy a drogové závislosti. Vorel F, Balíková M, Šejvl J. Smrtelná předávkování nelegálními drogami a těkavými látkami v ČR: Stručný souhrn a manuál pro monitorování. Úřad vlády ČR; 2004.

Sekretariát Rady vlády pro koordinaci protidrogové politiky. Národní strategie prevence a snižování škod spojených se závislostním chováním 2019-2027. Úřad vlády České republiky; 2019.

European Monitoring Centre for Drugs and Drug Addiction. Reitox network Available at: http://www.emcdda.europa.eu/about/partners/reitox-network (accessed 22 May 2019).

European Monitoring Centre for Drugs and Drug Addiction. An analysis of post-mortem toxicology practices in drug-related death cases in Europe. Luxembourg: Publications Office of the European Union, 2019.

England K. Coding and reporting of drug-related deaths in Europe. Part I: codification practices of drug related deaths following the WHO revision of ICD coding guidelines related to DRDs. Lisbon: EMCDDA, 2016.

England K. Coding and reporting of drug-related deaths in Europe. Part II: a review of the inventory of the national Special Mortality Registries in Europe, with a focus on information flow to the General mortality registries. Lisbon: EMCDDA, 2016.

England K. Coding and reporting of drug-related deaths in Europe. Part III: codification practices in some countries following the WHO revision. Lisbon: EMCDDA, 2016.

England K. To contribute to the EMCDDA review of drug related deaths from the GMR in some countries (including the codification practices of DRDs following the WHO revision of ICD coding guidelines). Lisbon: EMCDDA Meeting on DRDs, 2016.

Horon IL, Singal P, Fowler DR, Sharfstein JM. Standard death certificates versus enhanced surveillance to identify heroin overdose-related deaths. Am J Public Health 2018;108:777-81.

Hurstak E, Rowe C, Turner C et al. Using medical examiner case narratives to improve opioid overdose surveillance. Int J Drug Policy 2018;54:35-42.

Janssen E. Estimating the levels of acute drug-related deaths in France, 2001-2002: a simple technique to measure bias in overdoses recording. J Subs Use 2010;15:105-12.

Leifman H. Drug-related deaths in Sweden-estimations of trends, effects of changes in recording practices and studies of drug patterns. Sweden: The Swedish Council for Information on Alcohol and Other Drugs (CAN), 2016.

Uhl A, Hunt G, van den Brink W, Stimson GV. How credible are international databases for understanding substance use and related problems? Int J Drug Policy 2015;26:119-21.

Waal H, Gossop M. Making sense of differing overdose mortality: contributions to improved understanding of European patterns. Eur Addict Res 2013;20:8-15.

Millar T, McAuley A. EMCDA assessment of drug-induced death data and contextual information in selected countries. Lisbon, EMCDDA; 2017.

Kretschmerová T. Co je automatizované kódování příčin smrti 2006;48:143-8.

Institute of Health Information and Statistics of the Czech Republic. Zemřelí 2007. Praha: IHIS, 2008.Available at:. https://www.uzis.cz/sites/default/files/knihovna/demozem2007.pdf.

Zeileis A. Package ‘strucchange [R CRAN repository report]; 2019.

Gilmour S, Degenhardt L, Hall W, Day C. Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Med Res Methodol 2006;6:16.

Zeileis A, Kleiber C, Krämer W, Hornik K. Testing and dating of structural changes in practice. Comput Stat Data Anal 2003;44:109-23.

Griffiths P, Mravcik V, Lopez D, Klempova D. Quite a lot of smoke but very limited fire-the use of methamphetamine in Europe. Drug Alcohol Rev 2008;27:236-42.

Mravčík V, Chomynová P, Grohmannová K et al. Annual report on drug situation 2019-Czech Republic. Praha: Úřad vlády České republiky, 2019.

Verbesselt J, Zeileis A. Tutorial I: Detecting a breakpoint a time series; 2014.

Kim H-J, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.

Mravčík V, Grohmannová K, Chomynová P et al. Annual report on drug situation 2011-Czech Republic. Praha: Úřad vlády České republiky, 2012.

Cause-Specific Mortality among Patients in Treatment for Opioid Use Disorder in Multiple Settings: A Prospective Comparative Cohort Study